AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements
AIkido Pharma Inc. (Nasdaq: AIKI) announced on June 23, 2022, that it has regained compliance with NASDAQ's minimum bid price requirement of $1.00 for continued listing. The Company met this requirement when its common stock's closing bid price remained at or above $1.00 for 10 consecutive business days. This compliance matter is now closed, allowing AIkido to continue its operations on the NASDAQ Capital Market without the threat of delisting.
- Regained compliance with NASDAQ listing requirements.
- Maintained a closing bid price at or above $1.00 for 10 consecutive business days.
- None.
NEW YORK, June 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that on June 23, 2022, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company's platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-301576131.html
SOURCE AIkido Pharma Inc.
FAQ
What recent compliance achievement did AIkido Pharma Inc. announce on June 23, 2022?
What is the stock symbol for AIkido Pharma Inc.?
What does it mean for AIkido to regain compliance with NASDAQ?
How long did AIkido Pharma maintain its stock price to regain compliance?
